Investors & Media
News
SAGE Therapeutics to Present at Canaccord Genuity 34th Annual Growth Conference
A live webcast of the presentation can be accessed by visiting the investors section of the SAGE website at investor.sagerx.com. A replay of the webcast will be archived on the SAGE website one month following the presentation.
About
Forward-Looking Statements
Various statements in this release concerning SAGE's future
expectations, plans and prospects, including without limitation, SAGE's
expectations regarding SAGE-547 as a treatment for SRSE, the expected
development pathway for its other drug candidates and its expectations
with respect to the timing and success of its clinical trials,
constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors,
including, without limitation, SAGE's ability to successfully
demonstrate the efficacy and safety of its drug candidates, the
pre-clinical and clinical results for its product candidates, which may
not support further development of product candidates, actions of
regulatory agencies, which may affect the initiation, timing and
progress of clinical trials, obtaining, maintaining and protecting
intellectual property, SAGE's ability to enforce its patents against
infringers and defend its patent portfolio against challenges from third
parties, competition from others developing products for similar uses,
SAGE's ability to manage operating expenses, SAGE's ability to obtain
additional funding to support its business activities and establish and
maintain strategic business alliances and new business initiatives,
SAGE's dependence on third parties for development, manufacture,
marketing, sales and distribution of products, the outcome of
litigation, and unexpected expenditures, as well as those risks more
fully discussed in the section entitled "Risk Factors" in the final
prospectus related to SAGE's initial public offering filed with the
Media Contact:
dan@purecommunicationsinc.com
or
Investor
Contact:
monique@purecommunicationsinc.com
Source:
News Provided by Acquire Media